Pharmacy Times January 2, 2025
Key Takeaways
- NCPA calls for DOGE to target PBMs’ market dominance, which inflates profits and harms independent pharmacies and taxpayers.
- PBM reform could save taxpayers $5 billion by curbing anticompetitive practices like price fixing and patient steering.
- PBMs’ opaque practices and market power allow them to steer patients and set competitor prices, resisting transparency reforms.
- NCPA warns that current PBM practices could negatively impact Biden’s drug price negotiation program, risking pharmacy closures.
The big three PBMs rake in billions from government drug programs while patients pay more and small pharmacies are squeezed out, says NCPA
President-elect Donald Trump’s proposed Department of Government Efficiency (DOGE), an initiative led by Elon Musk and Vivek Ramaswamy, should zero in on the...
Today's Sponsors
Today's Sponsor